WeVote
Log In

Bill

Bill

A 2443

Relates to requiring insurance coverage for epinephrine auto-injectors

2025 Regular Session Introduced by Stacey Pheffer Amato and 1 co-sponsor

Bill A 2443 mandates insurance coverage for epinephrine auto-injectors, ensuring individuals at risk of severe allergies can access life-saving treatment affordably.

SUBSTITUTED BY S760
0
WeVote Research Nonpartisan
Bill Summary · A 2443

Summary of Bill A 2443

Overview

Bill A 2443 aims to require insurance coverage for epinephrine auto-injectors, which are critical devices used to treat severe allergic reactions (anaphylaxis). This legislation is designed to improve access to life-saving medication for individuals at risk of anaphylactic reactions.

Purpose and Intent

The primary intent of Bill A 2443 is to ensure that individuals who require epinephrine auto-injectors can obtain them without facing prohibitive costs. By mandating insurance coverage, the bill seeks to reduce financial barriers and promote public health safety.

Key Provisions

  • Insurance Coverage Requirement: The bill mandates that health insurance plans provide coverage for epinephrine auto-injectors, ensuring that patients can access these devices when needed.
  • Cost-Sharing Limits: While specific details on cost-sharing (such as copayments or deductibles) are not provided in the summary, the intent is to minimize out-of-pocket expenses for patients.
  • Accessibility: The bill emphasizes the importance of making epinephrine auto-injectors readily available to those who need them, potentially increasing the number of individuals who can afford and carry these devices.

Affected Parties

  • Individuals with Allergies: The primary beneficiaries of this legislation are individuals who are at risk of anaphylaxis due to allergies, including food allergies, insect stings, and certain medications.
  • Healthcare Providers: Medical professionals who prescribe epinephrine auto-injectors will be impacted by the changes in insurance coverage, as it may influence patient adherence to treatment plans.
  • Insurance Companies: Health insurance providers will need to adjust their policies and coverage plans to comply with the new requirements set forth by the bill.

Legislative Timeline

  • Introduced: January 17, 2025
  • Referred to Insurance Committee: January 17, 2025
  • Reported and Referred to Rules: January 28, 2025
  • Ordered to Third Reading: January 28, 2025
  • Substituted by S760: February 5, 2025

Related Legislation

  • S 760: This is the companion bill to A 2443, which has taken precedence following the substitution. The details of S 760 may provide further insights into the legislative intent and provisions regarding insurance coverage for epinephrine auto-injectors.

Conclusion

Bill A 2443 represents a significant step towards improving access to essential medical devices for individuals at risk of severe allergic reactions. By requiring insurance coverage for epinephrine auto-injectors, the bill aims to enhance public health outcomes and reduce financial burdens on patients. The subsequent substitution by S 760 indicates ongoing legislative efforts to address this critical health issue.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.